Product Details
Place of Origin: China
Brand Name: Sunshine
Certification: ISO,COA
Model Number: 13553-79-2
Payment & Shipping Terms
Minimum Order Quantity: Negotiation
Price: Negotiation
Packaging Details: Aluminum Foil Bag, Drum
Delivery Time: 7-15DAY
Payment Terms: L/C,D/A,T/T,D/P,Western Union,MoneyGram
Supply Ability: G,KG,TON
Appearance:: |
Yellow Orange Crystalline Powder |
CAS NO:: |
13553-79-2 |
Molecular Formula:: |
C37H45NO12 |
Molecular Weight:: |
695.75300 |
EINECS NO:: |
236-938-4 |
MDL NO:: |
MFCD06198807 |
Appearance:: |
Yellow Orange Crystalline Powder |
CAS NO:: |
13553-79-2 |
Molecular Formula:: |
C37H45NO12 |
Molecular Weight:: |
695.75300 |
EINECS NO:: |
236-938-4 |
MDL NO:: |
MFCD06198807 |
Product Description:
Product Name: Rifamycin S CAS NO: 13553-79-2
Synonyms:
O1,O4-didehydro-rifamycin;
NCI 144-130;
1,4-Dideoxy-1,4-dihydro-1,4-dioxorifamycin;
Chemical & Physical Properties:
Appearance: Yellow orange crystalline powder
Assay :≥98.0%
Density: 1.33 g/cm3
Boiling Point: 917.4℃ at 760 mmHg
Melting Point: 179-181℃ (dec.)
Flash Point: 508.6℃
Refractive Index: 1.605
Vapor Pressure: 0mmHg at 25℃
Safety Information:
HS Code: 2941903000
RTECS: KD1925000
Toxicity: LD50 in mice (mg/kg): 122 i.v.; 258 i.p.; 3000 orally (Sensi, 1964)
The rifamycins are a group of chemically related antibioticsobtained by fermentation from cultures of Streptomycesmediterranei. They belong to a class of antibiotics called theansamycins that contain a macrocyclic ring bridged acrosstwo nonadjacent positions of an aromatic nucleus. The termansa means “handle,” describing well the topography of thestructure. The rifamycins and many of their semisynthetic derivativeshave a broad spectrum of antimicrobial activity.They are most notably active against Gram-positive bacteriaand M. tuberculosis. However, they are also active againstsome Gram-negative bacteria and many viruses. Rifampin, asemisynthetic derivative of rifamycin B, was released as anantitubercular agent in the United States in 1971. A secondsemisynthetic derivative, rifabutin, was approved in 1992 forthe treatment of atypical mycobacterial infections.
If you are interested in our products or have any questions, please feel free to contact us!
Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.